Circle Pharma, Inc., a clinical-stage biopharmaceutical company pioneering next-generation targeted macrocycle therapeutics for cancer, today announced the nomination of CID-165, a first-in-class, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results